Table 1.
Participant characteristics
| Characteristic | Male participants |
Female participants |
||||
|---|---|---|---|---|---|---|
| Total | Positive for CT | Positive for NG | Total | Positive for CT | Positive for NG | |
| Age | ||||||
| 16–19 years | 15 (3.8) | 1 (6.7) | 0 | 40 (10.1) | 5 (12.5) | 0 |
| 20–24 years | 126 (32.1) | 22 (17.5) | 6 (4.8) | 157 (39.7) | 18 (11.5) | 0 |
| 25–34 years | 148 (37.8) | 11 (7.4) | 2 (1.4) | 140 (35.4) | 4 (2.9) | 1 (0.7) |
| 35–44 years | 64 (16.3) | 0 | 3 (4.7) | 41 (10.4) | 1 (2.4) | 1 (2.4) |
| 45–64 years | 37 (9.4) | 1 (2.7) | 1 (2.7) | 16 (4.1) | 0 | 0 |
| 65+ years | 2 (0.5) | 0 | 0 | 1 (0.3) | 0 | 0 |
| Clinic | ||||||
| 1 | 127 (32.4) | 13 (10.2) | 7 (5.5) | 157 (39.7) | 8 (5.1) | 2 (1.3) |
| 2 | 186 (47.4) | 18 (9.7) | 4 (2.2) | 161 (40.8) | 16 (9.9) | 1 (0.6) |
| 3 | 79 (20.2) | 4 (5.1) | 1 (1.3) | 77 (19.5) | 4 (5.2) | 0 |
| Contact | ||||||
| No | 340 (87.4) | 18 (5.3) | 10 (2.9) | 363 (92.8) | 16 (4.4) | 2 (0.6) |
| CT only | 33 (8.5) | 14 (42.4) | 2 (6.1) | 22 (5.6) | 11 (50.0) | 0 |
| NG only | 7 (1.8) | 2 (28.6) | 0 | 1 (0.3) | 0 | 1 (100) |
| Both CT and NG | 9 (2.3) | 1 (11.1) | 0 | 5 (1.3) | 0 | 0 |
| Received CT/NG active medication since test/6 weeks before test | ||||||
| No | 375 (95.7) | 34 (9.1) | 11 (2.9) | 367 (92.9) | 27 (7.4) | 3 (0.8) |
| Yes | 17 (4.3) | 1 (5.9) | 1 (5.9) | 28 (7.1) | 1 (3.6) | 0 |
| Symptomatic | ||||||
| No | 249 (63.7) | 18 (7.2) | 2 (0.8) | 208 (52.8) | 14 (6.7) | 1 (0.5) |
| Yes | 142 (36.3) | 16 (11.3) | 10 (7.0) | 186 (47.2) | 14 (7.5) | 2 (1.1) |
| Currently menstruating | ||||||
| No | 368 (93.4) | 28 (7.6) | 3 (0.8) | |||
| Yes | 26 (6.6) | 0 | 0 | |||
Data are presented as n (%). CT and NG positivity was defined as reference standard (positive by at least two of three tests: clinic NAAT, RPA CT/NG assay, Cepheid GeneXpert). Male participants were considered symptomatic if they reported one or more of: discharge (clear or cloudy liquid from penis); irritation at top of penis; itching; needing to pass urine more often than usual; pain/burning when urinating. Female participants were considered symptomatic if they reported one or more: itching; discharge (clear or cloudy liquid from vagina); pain/burning when urinating; needing to pass urine more frequently; pain during sex; bleeding after sex; bleeding in between periods; pelvic abdominal pain.
CT, Chlamydia trachomatis; NAAT, nucleic acid amplification test; NG, Neisseria gonorrhoeae; RPA, recombinase polymerase amplification.